DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

Information source: Ranbaxy Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acne

Intervention: Isotretinoin (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Ranbaxy Inc.

Official(s) and/or principal investigator(s):
Ashish Anvekar, MD, Study Director, Affiliation: Ranbaxy Laboratories Limited

Overall contact:
Neha Rana, Pharm D, Phone: 1-800-406-7984, Email: Drug.Safety@ranbaxy.com


This is an uncontrolled, open-label study being conducted in approximately 200 healthy males, non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne. ABSORICA« (isotretinoin) capsules 0. 5 mg/kg/day will be administered for 4 weeks followed by 1. 0 mg/kg/day for 16 weeks. Female subjects consenting to use two forms of birth control or abstinence are included.

Clinical Details

Official title: An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA« (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Quality of life (QOL) of subjects who are taking Absorica® (isotretinoin)

Secondary outcome:

Change from baseline in the lesion count

Change from baseline in the acne-quality of life (QOL) score

Change from baseline in the Investigator's Global Assessment (IGA)

Treatment safety (adverse events)

Treatment safety (local skin irritation)

Detailed description: This study is designed to collect efficacy, safety, and quality of life (QOL) data from subjects who receive Absorica« without food. The study will investigate the treatment efficacy, frequency of relapse once the treatment has been discontinued, quality of life during the active treatment and during a 2-year post treatment period and the overall safety of treatment with Absorica┬«. This is a single-arm, open-label study consisting of 2 phases: a 20-week (5-month) open-label Active Treatment Period (ATP) and a 104-week (2-year) post treatment period (PTP). The total study duration is to be 124 weeks, excluding a screening period. During the ATP, after week 2 visit, visits will be scheduled at 4-week intervals for a total of 8 visits (1 screening visit, 1 baseline visit, and 6 on-study visits). During the PTP, the first visit will be 4 weeks after End of Treatment (EOT), the second visit will be 12 weeks after EOT, and subsequent visits will be scheduled at 26-week (┬▒ 2 weeks) intervals for a total of 6 visits.


Minimum age: 12 Years. Maximum age: 45 Years. Gender(s): Both.


General Inclusion Criteria Subjects must meet the following mandatory inclusion criteria at the time of screening to be eligible to enter the study and must agree to conform to the requirements of the study and the iPLEDGE program.

- Written informed consent, including mandatory photographic consent, on a

gender-specific informed consent form (ICF) & Health Insurance Portability and Accountability Act (HIPAA) authorization prior to the performance of any study-related procedures.

- Pregnant females and females who are not to become pregnant during the ATP phase of

the trial and for 30 days after receiving their last dose of study drug.

- Female subjects of childbearing potential ready to use 2 forms of effective

contraception simultaneously for 1 month before starting Absorica® (isotretinoin), while taking Absorica® & for 1 month after Absorica® has been stopped.

- Male and female subjects of non-childbearing potential

Specific Inclusion Criteria:

- Severe recalcitrant nodular acne.

- Five or more nodule lesions on the face.

- Treatment-naïve subjects.

- Age between 12 and 45 years.

- Weight between 40 and 110 kg.

- Female subjects of childbearing potential only: Negative results from serum pregnancy

tests with a sensitivity of at least 25 milli-international unit/mL.

- Good general health as determined by the investigator based on the subject's medical

history, physical examination, vital signs measurements, and laboratory test results.

- Subjects who present with stable & controlled diabetes mellitus (Types I and II).

- Subjects with previously diagnosed polycystic ovarian syndrome (PCOS) can be included

in the study if in the opinion of the investigator they do not have any other clinically significant abnormality (eg, metabolic syndrome or elevated lipids Exclusion Criteria: General Exclusion Criteria

- Presence of any clinically significant physical examination finding, vital signs

measurement, or abnormal laboratory value;

- Presence of a beard or other facial hair that could interfere with the study


- Participated in another clinical trial or received an investigational product within

3 months prior to screening;

- History of excessive or suspected abuse of alcohol (based on the clinical judgment of

the investigator), recreational drugs, and/or drugs of abuse, e. g., club drugs, cocaine, ecstasy/MDMA (methylenedioxymethamphetamine), heroin, inhalants, marijuana, methamphetamine, phencyclidine, prescription medications, anabolic steroids, etc.

- Use of prohibited or restricted prior or concomitant medications. Female Specific

Exclusion Criteria

- Are pregnant;

- Are at a high risk for becoming pregnant or likely to become pregnant during


- Are breast-feeding or considering breast-feeding during the course of the study;

- Have a known history of PCOS with another clinically significant abnormality (eg,

metabolic syndrome or elevated lipids);

- Are unable or unwilling to maintain compliance with birth control measures

Locations and Contacts

Neha Rana, Pharm D, Phone: 1-800-406-7984, Email: Drug.Safety@ranbaxy.com

Texas Dermatology and Laser Specialists, San Antonio, Texas 78218, United States; Recruiting
Emily M Becker, MD, Principal Investigator
Kenneth W Dawes, MD, Principal Investigator
James Q. Del Rosso, DO, Principal Investigator
Douglass W Forsha, MD, Principal Investigator
Loyd Godwin, MD, Principal Investigator
Scott Thomas Guenthner, MD, Principal Investigator
Cheryl A Hull, MD, Principal Investigator
John Scott Kasteler, MD, Principal Investigator
David M Parsier, MD, Principal Investigator
Andrew K Pollack, MD, Principal Investigator
Rish Phoebe, MD, Principal Investigator
Scott Allen Smith, DO, Principal Investigator
Howard Sofen, MD, Principal Investigator
Melissa LF Knuckles, MD, Principal Investigator
Linda Francis Stein Gold, MD, Principal Investigator
Dowling B Stough, MD, Principal Investigator
Jeffery Sugarman, MD, PhD, Principal Investigator
Leonard J Swinyer, MD, Principal Investigator
John H Tu, MD, Principal Investigator
Andrea L Zaenglein, MD, Principal Investigator
Additional Information

Starting date: January 2015
Last updated: May 28, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017